Pancreatitis (acute)
Adverse events on the FDA labels, with the canonical evidence anchors.
Definition
Inflammation of the pancreas, listed as a labeled warning for every approved GLP-1 receptor agonist. Mechanism is uncertain but appears to involve cholelithiasis-triggered duct obstruction rather than direct pancreatic toxicity. Pooled FDA AERS data shows incidence ~0.2-0.4% over typical treatment durations — elevated vs background ~0.05%/year but absolute risk remains low. Patients with prior pancreatitis, heavy alcohol use, or symptomatic gallstones should weigh risk:benefit carefully.
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Side effects
Looking for more depth?
- Side-effect timeline tool
- Browse the full GLP-1 glossary (61 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers